Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company'...
Q1 2026
May 7, 2026
FY 2025
Mar 25, 2026
Q4 2025
Q3 2025
Nov 7, 2025
Q2 2025
Aug 8, 2025